Report indicates shift in strategy

A report released by Best Practices indicates that leading pharma and biopharmaceutical companies are rethinking their publication strategies, in light of new transparency guidelines.

“Traditional, global peer-reviewed journals remain the first choice of most companies at all phases of product development, but companies are increasingly exploring alternative media for scientific publications—50% of benchmark participants said they will be increasing the percentage of articles they submit to alternative media, such as e-journals, compared with 36% increasing submission to peer-reviewed journals,” said Martha Haswell, senior research analyst at Best Practices. 
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.